Telix Selects Cardinal Health As A Commercial Radiopharmaceutical Distributor To Supply Finished Unit Doses Of Its PET Agent Zircaix For Imaging Of Kidney Cancer In US
Portfolio Pulse from Benzinga Newsdesk
Telix has chosen Cardinal Health as the distributor for its PET agent Zircaix, used in imaging kidney cancer, in the US. This partnership aims to enhance the distribution of Zircaix, potentially impacting Cardinal Health's operations and market presence.
September 17, 2024 | 11:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cardinal Health has been selected by Telix as the distributor for Zircaix, a PET agent for kidney cancer imaging, in the US. This partnership could enhance Cardinal Health's market presence in the radiopharmaceutical sector.
The partnership with Telix to distribute Zircaix positions Cardinal Health to potentially increase its market share in the radiopharmaceutical sector. This could lead to increased revenues and strengthen its presence in the healthcare distribution market.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80